NCT02983097 - Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

April 28, 2015

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid VariantBurkitt Lymphoma (BL)Aggressive Marginal Zone Lymphoma (MZL)

Interventions

DRUG

Rituximab

Rituximab 375 mg/m²

DRUG

Cisplatin

Cisplatinum 100 mg / m²

DRUG

Carboplatin

Carboplatinum AUC5

DRUG

Dexamethasone

Dexamethasone 40 mg

DRUG

Cytarabine

Cytarabine 2000 mg/m², administered twice

DRUG

Lenalidomide

5-20 mg administered either d1-d7, or d-6-d7

DRUG

PegFilgrastim

PegFilgrastim 6 mg

PROCEDURE

peripheral stem cell collection

collection of peripheral stem cells for autologous stem cell transplantation

Trial Locations (12)

15236

Klinikum Frankfurt/Oder, Frankfurt (Oder)

20099

Asklepios Klinik St. Georg, Hamburg

22763

Asklepios Klinik Altona, Hamburg

28239

Diakonie Krankenhaus Bremen, Bremen

37075

Universitätsklinikum Göttingen, Göttingen

45122

Universitätsklinikum Essen, Essen

66421

Universitätsklinikum des Saarlandes, Homburg

67665

Westpfalz Klinikum, Kaiserslautern

69120

Universitätsklinikum Heidelberg, Heidelberg

76133

Städtisches Klinikum Karlsruhe, Karlsruhe

81377

LMU Klinikum München-Großhadern, München

09113

Klinikum Chemnitz, Chemnitz